Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKSNASDAQ:CINCNYSE:PBHNASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$29.35-2.3%$30.23$22.90▼$36.45$4.84B0.511.76 million shs2.01 million shsCINCCinCor Pharma$29.06-0.5%$29.08$10.53▼$43.15$1.27BN/A818,447 shs6.35 million shsPBHPrestige Consumer Healthcare$85.98+1.1%$83.52$62.35▼$90.04$4.25B0.44297,874 shs341,432 shsRYTMRhythm Pharmaceuticals$62.36+0.6%$58.83$35.17▼$68.58$3.97B2.36555,373 shs392,045 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-2.33%-6.59%+8.10%-16.92%+21.23%CINCCinCor Pharma0.00%0.00%0.00%0.00%0.00%PBHPrestige Consumer Healthcare+1.29%-3.65%+7.89%+1.56%+32.83%RYTMRhythm Pharmaceuticals+0.56%+4.05%+4.21%+11.22%+64.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.5583 of 5 stars4.41.00.04.23.11.71.9CINCCinCor PharmaN/AN/AN/AN/AN/AN/AN/AN/APBHPrestige Consumer Healthcare3.5793 of 5 stars1.33.01.73.52.42.51.9RYTMRhythm Pharmaceuticals4.1053 of 5 stars3.53.00.04.33.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.75Moderate Buy$38.3330.61% UpsideCINCCinCor Pharma 0.00N/AN/AN/APBHPrestige Consumer Healthcare 2.50Moderate Buy$93.338.55% UpsideRYTMRhythm Pharmaceuticals 3.00Buy$75.3820.89% UpsideCurrent Analyst Ratings BreakdownLatest CINC, ALKS, PBH, and RYTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025ALKSAlkermesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025PBHPrestige Consumer HealthcareRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/7/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$66.00 ➝ $72.005/2/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/2/2025ALKSAlkermesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$39.00 ➝ $40.005/2/2025ALKSAlkermesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$38.00 ➝ $41.004/28/2025ALKSAlkermesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderperform ➝ Underperform4/28/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform4/28/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$38.00 ➝ $33.004/8/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/8/2025RYTMRhythm PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$81.00 ➝ $92.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.51B3.20$2.20 per share13.32$9.05 per share3.24CINCCinCor PharmaN/AN/AN/AN/A($1.74) per shareN/APBHPrestige Consumer Healthcare$1.14B3.73$5.05 per share17.03$36.10 per share2.38RYTMRhythm Pharmaceuticals$136.86M28.99N/AN/A$2.87 per share21.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0913.5321.422.2023.57%30.80%19.09%7/23/2025 (Estimated)CINCCinCor Pharma-$50.37M-$17.28N/AN/AN/AN/A-33.03%-27.21%N/APBHPrestige Consumer Healthcare$209.34M$4.2920.1418.062.6919.13%12.36%6.39%N/ARYTMRhythm Pharmaceuticals-$184.68M-$2.81N/AN/AN/A-230.07%-367.36%-77.47%8/5/2025 (Estimated)Latest CINC, ALKS, PBH, and RYTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q4 2025PBHPrestige Consumer Healthcare$1.30$1.32+$0.02$1.00$289.36 million$296.52 million5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 million2/26/2025Q4 2024RYTMRhythm Pharmaceuticals-$0.69-$0.72-$0.03-$0.72$38.48 million$41.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ACINCCinCor PharmaN/AN/AN/AN/AN/APBHPrestige Consumer Healthcare$1.902.21%N/A44.29%N/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.042.65CINCCinCor PharmaN/A51.9651.96PBHPrestige Consumer Healthcare0.563.682.20RYTMRhythm PharmaceuticalsN/A3.493.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%CINCCinCor Pharma99.15%PBHPrestige Consumer Healthcare99.95%RYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%CINCCinCor Pharma15.60%PBHPrestige Consumer Healthcare1.60%RYTMRhythm Pharmaceuticals6.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes2,280164.90 million154.66 millionOptionableCINCCinCor Pharma1543.76 million36.94 millionNot OptionablePBHPrestige Consumer Healthcare54049.42 million48.75 millionOptionableRYTMRhythm Pharmaceuticals14063.62 million58.02 millionOptionableCINC, ALKS, PBH, and RYTM HeadlinesRecent News About These CompaniesDeutsche Bank AG Has $2.73 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 24 at 3:38 AM | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Position Trimmed by Frazier Life Sciences Management L.P.May 23 at 7:51 AM | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Rating of "Buy" by AnalystsMay 23 at 3:31 AM | americanbankingnews.comRafferty Asset Management LLC Sells 14,182 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 22 at 4:43 AM | marketbeat.comD. E. Shaw & Co. Inc. Buys 43,904 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 22 at 3:54 AM | marketbeat.comOMERS ADMINISTRATION Corp Takes $425,000 Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 21 at 4:55 AM | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of "Buy" from AnalystsMay 20, 2025 | marketbeat.comLazard Asset Management LLC Acquires New Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 18, 2025 | marketbeat.comJanus Henderson Group PLC Acquires 621,432 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 16, 2025 | marketbeat.comBNP Paribas Financial Markets Purchases 70,824 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 16, 2025 | marketbeat.comOrbimed Advisors LLC Reduces Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 15, 2025 | marketbeat.comRhythm FY Net Y758.00M Vs Net Y477.00MMay 14, 2025 | marketwatch.comRhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access ProgramMay 14, 2025 | globenewswire.comIntegral Health Asset Management LLC Invests $8.40 Million in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 14, 2025 | marketbeat.comNorthern Trust Corp Has $30.53 Million Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 13, 2025 | marketbeat.comHC Wainwright Has Negative Estimate for RYTM Q2 EarningsMay 13, 2025 | marketbeat.com138,363 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Acquired by Balyasny Asset Management L.P.May 12, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Purchased by The Manufacturers Life Insurance CompanyMay 12, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Acquired by Crestline Management LPMay 11, 2025 | marketbeat.comAlgert Global LLC Reduces Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 11, 2025 | marketbeat.comDriehaus Capital Management LLC Sells 8,515 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)May 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCINC, ALKS, PBH, and RYTM Company DescriptionsAlkermes NASDAQ:ALKS$29.35 -0.70 (-2.33%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$29.35 0.00 (0.00%) As of 05/23/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.CinCor Pharma NASDAQ:CINCCinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.Prestige Consumer Healthcare NYSE:PBH$85.98 +0.97 (+1.14%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$85.74 -0.24 (-0.27%) As of 05/23/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.Rhythm Pharmaceuticals NASDAQ:RYTM$62.36 +0.35 (+0.56%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$63.68 +1.32 (+2.12%) As of 05/23/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
